February 24, 2022 – Jardiance® (empagliflozin – Boehringer Ingelheim) is now indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults who have heart failure.

• Initially FDA approved in 2014, Jardiance is also indicated as an adjunct to diet and exercise to improve glycemic control in adults who have type 2 diabetes, and to reduce the risk of cardiovascular death in adults who have type 2 diabetes and established cardiovascular disease.
• Recommended dosing is 10mg once daily in the morning. For adults who have type 2 diabetes and require additional glycemic control, the dose can be increased to 25mg per day.